Prof Frederic Cadet’s Post

We are thrilled to announce that PEACCEL has been awarded the prestigious French DeepTech label by BPI France, the public investment bank dedicated to innovation. This recognition is a testament to our commitment to pushing the boundaries of biotechnology with our groundbreaking AI discovery platform for Biologics. 🔍 Our Platform's Impact: PEACCEL's AI-driven platform is transforming the pharmaceutical industry by enabling access to previously inaccessible spaces for drug discovery. Our technology makes it possible to identify novel, life-changing drugs by replicating processes that occur in nature only 1% of the time. This opens up new horizons in the quest for groundbreaking treatments. 💡 Why This Matters for VCs: PEACCEL's recognition by BPI France underscores our high quality and potential. With the DeepTech label, we gain easier access to public funding up to €15 million, alongside personalized support for our development. This is an unparalleled opportunity for venture capital investors looking to be part of a high-potential, innovative journey in the biotech space. We are on the brink of revolutionizing the pharmaceutical industry and invite VCs who share our vision of creating life-changing drugs through AI and biologics to join us on this exciting journey. Let's innovate and impact lives together. Reach out to learn more about how you can be part of this transformative venture. 🏅 About the French DeepTech Label: The DeepTech label from BPI France is reserved for companies that demonstrate strong growth potential and possess disruptive technologies. To be recognized, a company must innovate by overcoming technological barriers and present a significantly differentiating advantage over competitors. Read more…  https://lnkd.in/gd3gBPvY #DeepTech #venturecapital #aidrugdiscovery #pharmaceuticals #biologics

🌟 We are thrilled to announce that Exactmer has been selected for the Access2EIC pitching session during the EIC Summit in Brussels. 🚀 💊 Exactmer is a pioneering company that utilizes their revolutionary NanostarSieving technology to enable the production of precise polymeric pharmaceuticals. Their goal is to ensure that cutting-edge therapies are accessible to all patients in need.  🤝 In collaboration with CPI, AstraZeneca, Alnylam, and Novartis, Exactmer is actively addressing the challenges of achieving scalable, cost-effective, and sustainable production of oligonucleotides.  🔬 Exactmer engages in various development initiatives with their clients, leveraging NanostarSieving technology for oligonucleotide synthesis. With a total of 10 grants received since its inception, six of which remain active, Exactmer is continuously enhancing their technology for diverse applications. 💡 Their initiatives include exploring alternative chemistries for oligonucleotide synthesis, producing precise PEGs for use in PEGylated drugs, and developing multifunctional linkers for Antibody Drug Conjugates.  🌍🔬 Join us in celebrating Exactmer's groundbreaking work in advancing pharmaceutical production and making cutting-edge therapies more accessible to patients worldwide. Stay tuned for updates on their journey at the EIC Summit!  Access2EIC- EIC Summit Pitch session, organised by EuroQuity - Bpifrance in Brussels on March 18th will bring 7 deeptech companies already backed by EIC. #Access2EIC #EICSummit24 #bpifrance #vc #pitch #startup #eic #Exactmer #EICSummit #PharmaceuticalInnovation #NanostarSieving #HealthcareAdvancement

🚀 Financing in the IVD Sector! 🌟 In the first half of 2024, several leading IVD companies in China have achieved significant milestones in financing: Keylights Biotechnology secured nearly 100 million yuan in Series B financing to accelerate the commercialization of their diagnostic instruments. Targeting One completed nearly 100 million yuan in Series B+ financing for clinical trials, R&D, and market expansion of digital PCR products. Matridx raised several hundred million yuan in a C+ round to advance their pathogenic molecular diagnostic technology. Insigtech closed angel round financing to support their innovative healthcare solutions. Visionmedicals secured several hundred million yuan in Series D+ financing to further their diagnostic capabilities. Astrabio completed Pre-B+ round financing to fuel their growth in the biopharmaceutical sector. Cipher Gene raised 100 million yuan in Series C financing to expand their product offerings. Gensciences received investment from Tencent to advance their biopharmaceutical research and development. Chivybio completed Series A financing with a total of 100 million yuan. USK Biotech recently completed a new round of financing to strengthen their national market presence and advance new technology platforms. #IVD #Financing

Absolute huge news in the Pharma industry today! Pharma companies are set to deploy a record $1 trillion on new Biotech innovation deals, pending a rate cut from the federal reserve. Exciting times ahead for innovation and collaboration in the healthcare sector! #Pharma #Biotech #Innovation #Healthcare

* Isomorphic Labs, a closely watched AI biotech #startup, has signed its first pharma partnerships with Eli Lilly and Company and Novartis. * The two drugmakers are paying $82.5 million upfront, with $2.9 billion in potential milestones, to discover #drugs against undisclosed targets. * Isomorphic CEO Demis Hassabis said that the company is aiming to develop drugs that can actually cure #diseases, rather than just pilots and academic work. This is a significant development for Isomorphic Labs, which has been working on developing AI-powered drug discovery tools for several years. The company's technology uses #machinelearning to analyze large datasets of biological data in order to identify promising drug targets. The partnerships with Eli Lilly and Novartis will give Isomorphic Labs the resources it needs to bring its drugs to market. If Isomorphic Labs is successful in developing new drugs, it could have a major impact on the #pharmaceutical #industry. The company's AI-powered approach to drug discovery could lead to the development of new drugs that are more effective and less expensive than traditional drugs. It is still early days for Isomorphic Labs, but the company's recent partnerships with Eli Lilly and Novartis suggest that it is on the right track. Source: https://lnkd.in/dRGbKAjZ

Sanofi, a leader in pharmaceutical innovation, is bolstering its AI-driven drug discovery with a significant $140M collaboration with Parisian startup Aqemia. This multi-year partnership aims to develop small molecules across various therapeutic areas. Aqemia's unique approach combines theoretical physics and generative AI, enabling efficient molecule design without the need for supercomputers. This deal marks Sanofi's sixth AI-focused venture since 2021, underscoring its strategy to lead in AI-powered pharmaceuticals. Aqemia, also thriving, plans to double its team by 2024 and establish spinoff companies for each molecule developed, showcasing a dynamic fusion of AI and biotech. #AIinPharma #Sanofi #InnovativeDrugDiscovery

🚀 Exciting News in Biotech Innovation! Formation Bio Secures $372M Series D Funding 💡 Formation Bio, an AI-focused biotech company, has successfully raised $372 million in a series D funding round to further enhance its drug development capabilities. This funding, led by a16z with significant backing from Sanofi, will propel Formation Bio's mission to acquire and in-license clinical-stage assets, expanding their innovative pipeline. 🔍 What does this mean for the future of drug development? Formation Bio plans to leverage AI to streamline workflow automation in clinical trials, optimize patient recruitment, and accelerate decision-making in R&D processes. Their ambitious goal includes developing AI models to predict toxicity, tolerability, and efficacy—a transformative step forward in pharmaceutical research. 🌐 Currently, Formation Bio boasts a promising clinical pipeline, featuring candidates like gusacitinib for chronic hand eczema and ASN008 for conditions like notalgia paresthetica and atopic dermatitis itch. This funding round not only supports Formation Bio's growth but also signifies a significant investment in the future of AI-driven healthcare innovation. Stay tuned for more updates on their groundbreaking advancements! #BiotechInnovation #AIinHealthcare #SeriesDFunding #DrugDevelopment #ClinicalTrials #FormationBio #HealthTech #InnovationInPharma #Sanofi #a16z

Explore our latest White Paper on diving into the world of COVID-19 and what comes next, highlighting how biologics, rather than small molecules, took the lead in trials from 2019 to 2022, with the U.S., Europe, and China at the forefront. Download the White Paper- https://ow.ly/mkrH50QbnxZ and connect with one of our experts now- https://ow.ly/zFc850Qbny6 #Biotech #ClinicalTrials #Novotech

Exciting news from the world of biotech! Formation Bio, a leading AI-powered drug discovery company backed by OpenAI's CEO Sam Altman, has raised a remarkable £295 million in Series D funding. Led by Andreessen Horowitz, with significant participation from Sanofi, this investment will propel Formation's ambitious product roadmap and potentially transform the pharmaceutical industry. Why it Matters: Drug development is notoriously expensive and time-consuming. By leveraging AI, Formation aims to streamline clinical trials, optimise patient recruitment, and even predict drug efficacy and toxicity – all of which could drastically reduce costs and accelerate the delivery of life-saving medicines to patients. Formation Bio presents a compelling investment opportunity in the burgeoning field of AI-driven drug discovery with a new valuation well above its previous £800 million and significant backing from industry giants. The Future of Medicine: This substantial investment is a testament to the growing confidence in AI's potential to reshape healthcare. We are excited to see how Formation Bio continues to push boundaries and bring us closer to a future where new treatments are developed faster, more efficiently, and with greater success. #FormationBio #AI #DrugDiscovery #Biotech #InvestmentOpportunity #ladverts

Check out this interesting interview with Paul Agapow, Innovation Unit Director at GSK, discussing the best uses of GenAI in new drug research for Pharma and Biotech. Learn about what startups could benefit from using GenAI in this field! Find the link to the interview in the first comment. #GenAI #Pharma #BioTech #DrugResearch #Innovation #realitycheck